Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
does anyone know if stobf are involved with the break through in cancer treatment via immuno technology?
this was after 1:10 reverse stock split Sept. 2, 2015
company has fulfilled its commitments and continues to expand. price drop has more to do with flippers and shorts than than lack of potential
SBOTF did become SBOT with a reverse split of 10 to 1.
hence the uplist has been a loss for shareholders, at a great degree.
this company peogresses very slowly on KLH.
SBOT Presents Findings from Ongoing Research at Society for Glycobiology Meeting
Earlier today, Stellar Biotechnologies, Inc. (NASDAQ: SBOT) (TSX-V: KLH) announced the presentation of a preclinical poster relating to its ongoing research on Clostridium difficile. The poster, which was presented at the Society for Glycobiology 2015 Annual Meeting in San Francisco, California, reported data from the company’s studies into the potential development of C. difficile cell surface polysaccharide-KLH conjugate vaccines, or active immunotherapies, for the treatment of C. difficile infection.
Although C. difficile bacteria is normally present in the intestine, it sometimes overgrows as a result of antibiotic use. The infection that stems from this overgrowth has been linked to a host of dangerous side effects – including severe diarrhea and life-threatening intestinal conditions, such as colitis. Currently, the rate of U.S. cases of C. difficile overgrowth is at an all-time high. According to a 2011 study by the Centers for Disease Control and Prevention, C. difficile accounts for roughly 500,000 infections in the U.S. each year, costing patients and insurers approximately $4.8 billion in related medical expenses. Among those patients, an estimated 29,000 die within 30 days following initial diagnosis, further highlighting the importance of Stellar’s research program.
Stellar is the global leader in the sustainable manufacture of keyhole limpet hemocyanin (KLH) protein, which is an important immune-stimulating molecule widely used as an active pharmaceutical ingredient in immunotherapies. As a result of its proprietary method of sustainably producing GMP grade KLH, the company has partnered with a host of multinational pharmaceutical firms, renowned research centers and developers of active immunotherapies and therapeutic vaccines to address critically underserved indications in the biopharmaceutical industry.
Last month, the company successfully leveraged the marketability of its KLH protein by uplisting to the NASDAQ Capital Market. Following this move, Stellar reiterated intentions to expand its manufacturing capacity in order to better address the growing demand for KLH protein in immunotherapy. For prospective shareholders, the company’s recent progress represents an important step toward achieving sustainable corporate growth in the months to come.
To view the poster, Clostridium difficile Surface Polysaccharide-KLH Conjugate Vaccine Induced Th17-Featured Adaptive Immune Responses in Mice, visit http://content.equisolve.net/stellarbiotechnologies/media/0e37609debe1b998c4ccef5dd2a84a82.pdf
For more information, visit www.stellarbiotech.com
anyone know why no price, spread data showing or is there a board for SBOT
nice opening between $9.5-$10 range give pps a couple of weeks to settle then move north.
SBOTF moved from the OTC to the Nasdaq:
http://otce.finra.org/DLDeletions
what ever happens tomorrow it will be good to be on an exchange where the company performance matters more than its flip ability.
come to think of it ringing NASDAQ the bell at close in marketing terms must be the equivalent of an add mid way through the super bowl. priceless. need to buy more.
The shells are big enough.Lets hope its heard world wide be nice to see some fireworks
Exposure is a good thing.
Wonder if they smack the closing bell with a Keyhole Limpet shell.
Can only be for the good to lift SBOTF out of the mire that is he OTC.Exposure to institutional investors with a product produced no where else should be a winner. Increasing use as a carrier in new drugs under FDA approval, expansion of production and increased revenues all looks good for future PPS jmo
Hey Coddy, What's your thoughts on the uplisting to the Nasdeq?
More exposure to more investors or just an opportunity to ring the closing bell November 5th.
They did what they said they wanted to do but can they produce what they want to produce?
Sorry for all the "they" references.
Just read a report on Stellar by Seeking Alpha very interesting, summary, production of KLM up from 2kg to 20kg and earnings in £100million over next 10 years and based on the financial formula they used price today around $7 is way under value should be £13.Looking forward to up-listing to NASDAQ.
would be nice if one of their clients got FDA approval to coincide with up list to NASDAQ
no not shore but believe they are waiting on approval,30 day $4 pps basic requirement
Are you sure? Another company I am invested in did the RS and uplisting to the Nasdaq on the same day.
There was not a 30 day lag between them.
needs to stay above $4 for 30 days to be able to up list to NASDAQ
Wow. So far so good. With this few shares it will swing wildly on any news.
SBOTF is now SBOTD
SBOTF one for 10 reverse split:
http://otce.finra.org/DLSymbolNameChanges
Right you are Coddy, just reread and there was a sentence that stated no gaurntees. My bad, there was too much tropical storm Erika down here at the time.
as i read the pr nothing is definite yet
Should the current price hold, SBOT will be seen on the NASDEQ for the first time in the $9 range on Tuesday.
As a supply company that is expanding you should only expect that to happen. Stellar is going to ride the coattails of any successful drugs related to traceable KLH. Until that happens, the business cycle remains the same.
Does anyone know if they plan to conduct a private placement of shares in conjunction with this offering?
I went through a RS with another stock lately and it consisted of a private placement in conjunction with the RS.
There were several lessons learned.
That's why up big today!
RS September 2nd 10 to 1
I think it is if that's what you have to do to get listed on NASDAQ.
my experience of R/S has never been good but in conjunction of up listing would be acceptable if supported by positive news concerning fda approval of customer drugs
Look for a RS 5 or 6 to 1 & uplisting to NASDAQ, possible this year or next.
old news(2013) anything more recent to add?
Stellar Biotechnologies – The real deal or just more tulip bulbs?
http://www.stockgumshoe.com/2013/08/microblog-stellar-biotechnologies-the-real-deal-or-just-more-tulip-bulbs/
Moneymappress.com says their going to do in-depth look at our "Living Metals" stock this Tuesday at 6.00 pm.
its my understanding several of their clients using klh have drugs for fda approval
Won't be a lot of interest here until NASDAQ....if ever this happens.
Their Keyhole Limpet Hemocyanin (KLH) molecule has potential for 100 of millions of sales as companies are starting to buy it. Still a very high spec play.
A widely followed national paid for subscription newsletter I subscribe to likes them a lot. They say they're preparing to uplist to NASDAQ
Smaller company but has a lot of potential;
http://ir.stellarbiotechnologies.com/all-sec-filings#document-7463-0001144204-15-047755
SBOTF surged yesterday to 0.58 after a very deceptive half-year
interesting collaboration
Jul 28 2015
Stellar Biotechnologies Signs Collaboration Agreement to Expand KLH Aquaculture Operations can be viewed on web site
looks like they reigned back R/D into new drugs and concentrated on production of limpets wise move stopped the cash burn
$SBOTF recent news/filings
bullish
## source: finance.yahoo.com
Tue, 21 Jul 2015 17:04:06 GMT ~ STELLAR BIOTECHNOLOGIES, INC. Financials
read full: http://finance.yahoo.com/q/is?s=sbotf&annual
*********************************************************
Fri, 17 Jul 2015 17:04:08 GMT ~ STELLAR BIOTECHNOLOGIES, INC. Financials
read full: http://finance.yahoo.com/q/is?s=sbotf
*********************************************************
Thu, 09 Jul 2015 12:30:00 GMT ~ Stellar Biotechnologies Retains The Ruth Group to Advance Communications Objectives
[Marketwired] - Stellar Biotechnologies, Inc. , a leading provider of Keyhole Limpet Hemocyanin protein, a crucial component for the development of many novel immunotherapies, today announced that it has retained New ...
read full: http://finance.yahoo.com/news/stellar-biotechnologies-retains-ruth-group-123000852.html
*********************************************************
Mon, 15 Jun 2015 11:19:08 GMT ~ STELLAR BIOTECHNOLOGIES, INC. Files SEC form 8-K, Other Events
read full: http://biz.yahoo.com/e/150615/sbotf8-k.html
*********************************************************
Mon, 01 Jun 2015 12:30:00 GMT ~ Stellar Biotechnologies to Present at 5thAnnual LD Micro Invitational
[Marketwired] - Stellar Biotechnologies, Inc. today announced that Stellar executives will present at the 5th Annual LD Micro Invitational Conference, being held June 1-3, 2015 at the Luxe Sunset Boulevard Hotel, Los ...
read full: http://finance.yahoo.com/news/stellar-biotechnologies-present-5thannual-ld-123000787.html
*********************************************************
$SBOTF charts
basic chart ## source: stockcharts.com
basic chart ## source: stockscores.com
big daily chart ## source: stockcharts.com
big weekly chart ## source: stockcharts.com
$SBOTF company information
## source: otcmarkets.com
Link: http://www.otcmarkets.com/stock/SBOTF/company-info
Ticker: $SBOTF
OTC Market Place: OTCQB
CIK code: 0001540159
Company name: Stellar Biotechnologies Inc.
Company website: http://www.stellarbiotechnologies.com
Incorporated In: British Columbia, Canada
Business Description: Stellar Biotechnologies, Inc. (OTCQB: SBOTF) (TSX VENTURE: KLH) is the leader in sustainable manufacture of Keyhole Limpet Hemocyanin (KLH), an important immune-stimulating protein used in wide-ranging therapeutic and diagnostic markets. KLH is both an active pharmaceutical ingredient (API) in many new immunotherapies (targeting cancer, immune disorders, Alzheimer's and inflammatory diseases) as well as a finished product for measuring immune status. Stellar Biotechnologies is unique in its proprietary methods, facilities, and KLH technology. We are committed to meeting the growing demand for commercial-scale supplies of GMP grade KLH, ensuring environmentally sound KLH production, and developing KLH-based active immunotherapies.Visit www.stellarbiotech.com and the KLH knowledge base www.klhsite.org.Less >>
$SBOTF share structure
## source: otcmarkets.com
Market Value: $59,659,988 a/o Jul 21, 2015
Shares Outstanding: 79,546,650 a/o Dec 19, 2014
Float: Not Available
Authorized Shares: Unlimited a/o Dec 10, 2014
Par Value: No Par Value
$SBOTF extra dd links
Company name: Stellar Biotechnologies Inc.
Company website: http://www.stellarbiotechnologies.com
## STOCK DETAILS ##
After Hours Quote (nasdaq.com): http://www.nasdaq.com/symbol/SBOTF/after-hours
Option Chain (nasdaq.com): http://www.nasdaq.com/symbol/SBOTF/option-chain
Historical Prices (yahoo.com): http://finance.yahoo.com/q/hp?s=SBOTF+Historical+Prices
Company Profile (yahoo.com): http://finance.yahoo.com/q/pr?s=SBOTF+Profile
Industry (yahoo.com): http://finance.yahoo.com/q/in?s=SBOTF+Industry
## COMPANY NEWS ##
Market Stream (nasdaq.com): http://www.nasdaq.com/symbol/SBOTF/stream
Latest news (otcmarkets.com): http://www.otcmarkets.com/stock/SBOTF/news - http://finance.yahoo.com/q/h?s=SBOTF+Headlines
## STOCK ANALYSIS ##
Analyst Research (nasdaq.com): http://www.nasdaq.com/symbol/SBOTF/analyst-research
Guru Analysis (nasdaq.com): http://www.nasdaq.com/symbol/SBOTF/guru-analysis
Stock Report (nasdaq.com): http://www.nasdaq.com/symbol/SBOTF/stock-report
Competitors (nasdaq.com): http://www.nasdaq.com/symbol/SBOTF/competitors
Stock Consultant (nasdaq.com): http://www.nasdaq.com/symbol/SBOTF/stock-consultant
Stock Comparison (nasdaq.com): http://www.nasdaq.com/symbol/SBOTF/stock-comparison
Investopedia (investopedia.com): http://www.investopedia.com/markets/stocks/SBOTF/?wa=0
Research Reports (otcmarkets.com): http://www.otcmarkets.com/stock/SBOTF/research
Basic Tech. Analysis (yahoo.com): http://finance.yahoo.com/q/ta?s=SBOTF+Basic+Tech.+Analysis
Barchart (barchart.com): http://www.barchart.com/quotes/stocks/SBOTF
DTCC (dtcc.com): http://search2.dtcc.com/?q=Stellar+Biotechnologies+Inc.&x=10&y=8&sp_p=all&sp_f=ISO-8859-1
Spoke company information (spoke.com): http://www.spoke.com/search?utf8=%E2%9C%93&q=Stellar+Biotechnologies+Inc.
Corporation WIKI (corporationwiki.com): http://www.corporationwiki.com/search/results?term=Stellar+Biotechnologies+Inc.&x=0&y=0
WHOIS (domaintools.com): http://whois.domaintools.com/http://www.stellarbiotechnologies.com
Alexa (alexa.com): http://www.alexa.com/siteinfo/http://www.stellarbiotechnologies.com#
Corporate website internet archive (archive.org): http://web.archive.org/web/*/http://www.stellarbiotechnologies.com
## FUNDAMENTALS ##
Call Transcripts (nasdaq.com): http://www.nasdaq.com/symbol/SBOTF/call-transcripts
Annual Report (companyspotlight.com): http://www.companyspotlight.com/library/companies/keyword/SBOTF
Income Statement (nasdaq.com): http://www.nasdaq.com/symbol/SBOTF/financials?query=income-statement
Revenue/EPS (nasdaq.com): http://www.nasdaq.com/symbol/SBOTF/revenue-eps
SEC Filings (nasdaq.com): http://www.nasdaq.com/symbol/SBOTF/sec-filings
Edgar filings (sec.gov): http://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001540159&owner=exclude&count=40
Latest filings (otcmarkets.com): http://www.otcmarkets.com/stock/SBOTF/filings
Latest financials (otcmarkets.com): http://www.otcmarkets.com/stock/SBOTF/financials
Short Interest (nasdaq.com): http://www.nasdaq.com/symbol/SBOTF/short-interest
Dividend History (nasdaq.com): http://www.nasdaq.com/symbol/SBOTF/dividend-history
RegSho (regsho.com): http://www.regsho.com/tools/symbol_stats.php?sym=SBOTF&search=search
OTC Short Report (otcshortreport.com): http://otcshortreport.com/index.php?index=SBOTF
Short Sales (otcmarkets.com): http://www.otcmarkets.com/stock/SBOTF/short-sales
Key Statistics (yahoo.com): http://finance.yahoo.com/q/ks?s=SBOTF+Key+Statistics
Insider Roster (yahoo.com): http://finance.yahoo.com/q/ir?s=SBOTF+Insider+Roster
Income Statement (yahoo.com): http://finance.yahoo.com/q/is?s=SBOTF
Balance Sheet (yahoo.com): http://finance.yahoo.com/q/bs?s=SBOTF
Cash Flow (yahoo.com): http://finance.yahoo.com/q/cf?s=SBOTF+Cash+Flow&annual
## HOLDINGS ##
Major holdings (cnbc.com): http://data.cnbc.com/quotes/SBOTF/tab/8.1
Insider transactions (yahoo.com): http://finance.yahoo.com/q/it?s=SBOTF+Insider+Transactions
Insider transactions (secform4.com): http://www.secform4.com/insider-trading/SBOTF.htm
Insider transactions (insidercrow.com): http://www.insidercow.com/history/company.jsp?company=SBOTF
Ownership Summary (nasdaq.com): http://www.nasdaq.com/symbol/SBOTF/ownership-summary
Institutional Holdings (nasdaq.com): http://www.nasdaq.com/symbol/SBOTF/institutional-holdings
Insiders (SEC Form 4) (nasdaq.com): http://www.nasdaq.com/symbol/SBOTF/insider-trades
Insider Disclosure (otcmarkets.com): http://www.otcmarkets.com/stock/SBOTF/insider-transactions
## SOCIAL MEDIA AND OTHER VARIOUS SOURCES ##
PST (pennystocktweets.com): http://www.pennystocktweets.com/stocks/profile/SBOTF
Market Watch (marketwatch.com): http://www.marketwatch.com/investing/stock/SBOTF
Bloomberg (bloomberg.com): http://www.bloomberg.com/quote/SBOTF:US
Morningstar (morningstar.com): http://quotes.morningstar.com/stock/s?t=SBOTF
Bussinessweek (businessweek.com): http://investing.businessweek.com/research/stocks/snapshot/snapshot_article.asp?ticker=SBOTF
$SBOTF DD Notes ~ http://www.ddnotesmaker.com/SBOTF
MM trying to walk down he ask again, pure manipulation
Followers
|
20
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
290
|
Created
|
09/10/10
|
Type
|
Free
|
Moderators |
Bio-tech with a new cancer protein system.
Stellar Biotechnologies Files Key Patent for Company
9/9/2010 8:04:21 AM - Market Wire
PT. HUENEME, CA, Sep 09, 2010 (MARKETWIRE via COMTEX News Network) --
Stellar Biotechnologies, Inc. (PINKSHEETS: SBOTF) (TSX-V: KLH) announces filing for patent protection of inventions related to its native Immunogenic (IMG) KLH technology platform and immune status monitoring product portfolio. KLH (keyhole limpet hemocyanin) is presently the most pharmaceutically important ICP (immune carrier protein) and IMG KLH is the most effective immune stimulant for use in cancer, viral and parasite vaccines; animal vaccines; and diagnostic products. Patent claims include pharmaceutical grade compositions of matter, processes for manufacture and methods of use in a wide range of therapies.
John Sundsmo, Ph.D., VP Research and Intellectual Property, said, "With filing of this patent application Stellar has achieved an important milestone on the road to becoming the preeminent world leader in development and manufacture of pharmaceutical grade immune carrier proteins. We are very pleased with the progress achieved by our scientists and what this patent application tangibly demonstrates."
Corporate Website: www.StellarBiotechnologies.com Stellar News at Marketwire: http://www.marketwire.com/mw/search.do?params=&grpSearch=C&companyid=70788
About Stellar Biotechnologies, Inc. (PINKSHEETS: SBOTF) (TSX-V: KLH) - (www.StellarBiotechnologies.com): is a world leader in sustainable manufacturing of pharmaceutical grade immune carrier proteins (ICP), particularly with regard to the present most important pharmaceutical protein in this class, KLH (Keyhole Limpet Hemocyanin). This ancient evolutionary protein has a highly complex structure that makes it ideal for use in human and animal vaccines and diagnostic products. With partners and customers, its flagship Stellar KLH products are in the clinic, and on the way to being established as the only sustainable, long-term pharmaceutical source.
This news release does not constitute an offer to sell, or a solicitation of an offer to buy any of the Company's securities set out herein in the United States, or to, or for the benefit or account of, a U.S. Person or person in the United States. Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
Contact: Darrell Brookstein Executive VP, Business Development & Finance dbrookstein@stellarbiotech.com
SOURCE: Stellar Biotechnologies, Inc.
mailto:dbrookstein@stellarbiotech.com
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |